Ajanta Pharma Ltd - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Ajanta Pharma has uploaded the audio recording of its earnings call for Q1 FY27, conducted on July 30, 2026, to its official website. This provides investors access to the discussion about the company's recent financial performance.
Jul 30 2026 17:38:42
Ajanta Pharma Ltd - 532331 - Record Date Intimation For Dividend
Ajanta Pharma fixed August 5, 2026, as the Record Date. This date is for determining shareholders eligible for the 1st interim dividend.
Jul 30 2026 14:43:56
Ajanta Pharma Ltd - 532331 - Corporate Action-Board approves Dividend
Ajanta Pharma declared a ₹32 interim dividend per share (face value ₹2) for FY27, with a total payout of ₹400 crores. The record date is August 5, 2026, and payment will be on or after August 18, 2026.
Jul 30 2026 14:42:33
Ajanta Pharma Ltd - 532331 - Board Meeting Outcome for BM Outcome
Ajanta Pharma reported robust Q1 FY27 consolidated financial results with revenue up 25% to ₹1,626 cr and net profit rising 31% to ₹334 cr. The board also approved a ₹32 interim dividend per share for FY27.
Jul 30 2026 14:35:43
Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Ajanta Pharma promoter Aayush Agrawal re-pledged 21.61 lakh shares (1.73% of total share capital) on July 24, 2026. This action serves as security for the issuance of new non-convertible debentures, with no net change in pledged holding.
Jul 29 2026 12:23:10
Ajanta Pharma Ltd - 532331 - Update on board meeting
Ajanta Pharma's Board will convene on July 30, 2026, to consider the Q1 FY27 financial results and the declaration of the first interim dividend for FY27. If declared, August 5, 2026, will be the record date for the dividend payment.
Jul 20 2026 10:51:10
Ajanta Pharma Ltd - 532331 - Board Meeting Intimation for Board Meeting Scheduled To Be Held On 30Th July 2026.
Ajanta Pharma announced its Board will meet on July 30, 2026. The meeting's agenda includes considering and approving the unaudited consolidated and standalone financial results for the first quarter ended June 30, 2026. This is a routine quarterly update for investors.
Jul 20 2026 10:43:20
Ajanta Pharma Ltd - 532331 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Ajanta Pharma's promoter group entities, Aayush M. Agrawal, Aayush M. Agrawal (Trustee), and Gabs Investments Pvt Ltd, pledged a total of 66.33 lakh shares. This represents approximately 5.31% of the company's total paid-up share capital. The shares were pledged as security for the issuance of non-convertible debentures.
Jul 08 2026 14:13:25
Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
Ajanta Pharma's promoter group has pledged 6.63 million shares, equivalent to 5.31% of the company's total equity, as security for debentures worth approximately Rs. 3873 crore. This move indicates increased leverage by promoter entities.
Jul 03 2026 11:12:14
Ajanta Pharma Ltd - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Promoters Aayush Agrawal Trust and Aayush Agrawal pledged 1,006,726 shares of Ajanta Pharma, amounting to 0.80% of the total share capital. This pledge was made to secure a new loan from CTL Trusteeship Limited.
Jul 03 2026 10:31:10
Read More